
ProMetic was founded in 1994. The scientists at ProMetic Life Sciences are meticulous about proteins. The biotech company develops protein technologies for pharmaceutical, diagnostic, and blood and plasma product development. ProMetic's Protein Technologies division licenses its technologies to companies around the globe, who then make their own products. The company's Therapeutics division conducts proprietary drug development programs for blood disease and cancer therapeutics. The company has collaborative agreements with pharmaceutical companies and health organizations such as Abraxis BioScience, Merck Serono, and The American Red Cross.

BioMS Medical Corp. was founded in 1998 and is headquartered in Edmonton, Canada. BioMS Medical Corp., a development stage biotechnology company, through its subsidiaries, engages in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS) in Canada. Its lead product under development includes Dirucotide for the treatment of multiple sclerosis, which is being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients; and MAESTRO-01, a pivotal phase II/III trial in Canada and western Europe. The company also develops Maestro-02, an open-label follow-on study to the Maestro-01 pivotal phase II/III clinical trial of Dirucotide, which targets secondary progressive multiple sclerosis (SPMS), as well as MAESTRO-03 trial, a pivotal Phase III product to evaluate the safety and efficacy of Dirucotide in patients with SPMS in the United States. BioMS Medical Corp. has a licensing and development agreement with Eli Lilly and Company. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in July 2001.

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

ARIUS Research Inc. company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG. ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited.

Genencor manufactures genetically modified enzymes for the industrial, agricultural, and consumer products markets. Using its biotechnology know-how, the company discovers useful enzymes (naturally occurring protein catalysts) and develops them for mass production; the enzymes are used in myriad ways, including as additives in animal feed and detergents, as a method of converting starch into ethanol, and in the production of textiles and paper. Genencor International is a division of food ingredient company Danisco.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

Since its inception in 1982, AIM International, Inc. has made and marketed food concentrates and nutritional supplements through direct sales and through "members" who sell and distribute in a multilevel marketing arrangement. On the company's 25th anniversary, CEO Dennis Itami added a personal-care line to the product mix. The company's roster also includes a line of supplements for athletes. AIM International (dba The AIM Companies) has offices in Australia, Canada, New Zealand, South Africa, and the UK. Lead products include AIM BarleyLife and AIMega.

AspenBio Pharma, Inc. company was founded in 2000 and is based in Castle Rock, Colorado. AspenBio Pharma, Inc. (AspenBio) is a biotechnology company engaged in the discovery, development, manufacture, and licensing or marketing of products. The Company is primarily focused on advancing towards commercialization its blood-based human diagnostic test, AppyScore to aid in the diagnosis of human appendicitis and several reproduction drugs for use in high value animals. AppyScore is a blood-based test to the aid in diagnosis of appendicitis. AppyScore measures the abundance of MRP 8/14, an inflammation biomarker, which AspenBio has identified to be elevated in acute appendicitis and demonstrates a correlation to the severity of the disease. In December 2008, the Company completed an 800 patient pivotal clinical trial for AppyScore. Products in its pipeline consist of product candidates in various stages of clinical and pre-clinical development.

Henderson Morley takes aim at those pesky microscopic parasites we know as viruses. The company researches and develops vaccines and treatments for viral infections by preventing them from replicating once they invade their host cells. One of its lead product candidates is a vaccine for genital herpes that could be used as a preventative or a therapeutic measure. Other candidates target human cytomegalovirus and human papillomavirus. Instead of taking its candidates through all phases of development, Henderson Morley instead looks to out-license its candidates. Chairman Andrew Knight owns 34% of the company.

Corgenix Medical Corporation company was founded in 1985 and is headquartered in Broomfield, Colorado. Corgenix Medical Corporation, together with its subsidiaries, engages in the research, development, manufacture, and marketing of in vitro diagnostic products for use in disease detection and prevention in the United States and internationally. The company offers autoimmune disease products that are used for the diagnosis and monitoring of autoimmune diseases, including RA, SLE, mixed connective tissue diseases, Sjogrens Syndrome, Dermatopolymyositis, and Scleroderma; and antiphospholipid antibody testing products, which are used in the diagnosis of clotting and bleeding disorders, including von Willebrand's disease. It also provides AspirinWorks, a urine test kit that measures an individual's response to aspirin dosage and allows physicians to adjust the dosage or recommend alternative therapy; and liver disease products, which include hyaluronic acid, a component of the matrix of connective tissues found in synovial fluid of the joints where it acts as a lubricant and for water retention. The company sells its products to hospitals, clinical testing laboratories, universities, biotechnology and pharmaceutical companies, and research institutions. It markets its products through a network of sales representatives, distributors, and private label agreements.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






